Critical

Neonatal supraventricular tachycardia (SVT)

Narrow-complex tachycardia in the newborn · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Neonatal SVT is a regular narrow-complex tachycardia, usually from an accessory pathway (AV re-entrant tachycardia), typically with rates around 220–300/min and little beat-to-beat variability. Prolonged SVT can cause heart failure and cardiovascular collapse and requires prompt termination.

Red flags

  • Signs of shock or heart failure
  • Reduced conscious level or poor perfusion
  • Very prolonged SVT (risk of tachycardia-induced cardiomyopathy)
  • Broad-complex tachycardia (treat as VT until proven otherwise)
  • Recurrent SVT despite treatment

Assessment

Differential diagnosis

  • Sinus tachycardia (secondary to sepsis, pain, fever, hypovolaemia)
  • Atrial flutter
  • Ventricular tachycardia (broad complex)
  • SVT with aberrancy
  • Congenital heart disease with arrhythmia
  • Metabolic/electrolyte disturbance or drug effect

Investigations

  • 12-lead ECG (and rhythm strip) to confirm rate, QRS width and P-wave relationship
  • Continuous cardiac monitoring and SpO2
  • Echocardiography to assess structure and ventricular function
  • Electrolytes, calcium, magnesium, glucose
  • Blood gas and lactate (assess perfusion)
  • Sepsis screen if sinus tachycardia possible

Management

  • Confirm the rhythm: narrow-complex, very fast, regular, minimal rate variability (distinguish from sinus tachycardia which varies and is usually <220/min).
  • Assess haemodynamic stability (perfusion, BP, conscious level, signs of heart failure).
  • Attach continuous monitoring, obtain IV/IO access and a 12-lead ECG, and record the rhythm during any intervention.
  • In a STABLE infant, attempt vagal manoeuvres first: apply a bag of iced water/ice to the face (diving reflex) for a few seconds.
  • If vagal manoeuvres fail in a stable infant with reliable IV access, give rapid-push adenosine via a large proximal vein with immediate saline flush, escalating the dose if needed.
  • Record a continuous ECG during adenosine to capture the mechanism of termination.
  • In an UNSTABLE infant (shock/collapse), perform urgent synchronised DC cardioversion.
  • Correct contributing factors: electrolytes, acidosis, temperature and treat heart failure.
  • After conversion, obtain a 12-lead ECG looking for pre-excitation (delta wave/WPW).
  • Involve paediatric cardiology for maintenance therapy and to plan longer-term management.
  • Start maintenance anti-arrhythmic therapy to prevent recurrence as advised by cardiology.
  • Educate parents on recurrence and when to seek help; arrange cardiology follow-up.

Drugs & doses

Adenosine 0.1 mg/kg (100 microgram/kg) rapid IV/IO bolus with immediate flush; increase to 0.2 then up to 0.3 mg/kg if needed
Synchronised DC cardioversion 1 J/kg, increasing to 2 J/kg for the unstable infant
Flecainide or propranolol (e.g. propranolol 0.25–1 mg/kg/dose PO 6–8-hourly) for maintenance, under cardiology guidance
Amiodarone 5 mg/kg IV over 20–60 min (specialist use) for refractory tachyarrhythmia
Avoid verapamil in infants (risk of profound hypotension and arrest)

Disposition

NICU/PICU-level monitoring with cardiology involvement; stabilise, start maintenance therapy and arrange cardiology follow-up and family education.

Complications & pitfalls

  • Cardiogenic shock and collapse
  • Tachycardia-induced cardiomyopathy and heart failure
  • Recurrence requiring long-term therapy
  • Adverse effects of anti-arrhythmics (bradycardia, hypotension)
  • Rarely, association with structural heart disease

Exam pearls

  • Sinus tachycardia varies with activity and is usually <220/min; SVT is fast, fixed and monotonous.
  • Adenosine must be given as a rapid push into a large vein with an immediate flush to work.
  • Record a continuous ECG during adenosine – it is diagnostic as well as therapeutic.
  • Avoid verapamil in neonates and young infants.
  • An unstable infant needs synchronised cardioversion, not repeated drug attempts.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.